GlobalData on MSN6d
EC approves AstraZeneca’s Fasenra for EGPA treatment
Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...
GlobalData on MSN1mon
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with ...
biopharma-reporter6d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
The Pharma Letter7d
EU approval for Fasenra in eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients ...
Medscape6d
Fasenra Approved in Europe for Rare Blood Vessel Disorder
The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...
AstraZeneca’s Fasenra approved in EU for EGPA
Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or ...
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up ...
Pharmabiz6d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
Yahoo Finance1mon
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma ...
PharmiWeb7d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
Nasdaq7d
AstraZeneca’s Fasenra approved in EU for EGPA
AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
Yahoo Finance6d
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a ...